Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Model reveals genes associated with prognosis in ER+, HER2– breast cancer

Key clinical point: A prognostication model identified genes in the tumor microenvironment that are strongly associated with worse prognosis in stage III, estrogen receptor-positive, HER2-negative breast cancer.

Major finding: Kaplan-Meier curves showed a significant survival difference in the high- and low-risk groups (hazard ratio, 2.878; P = .05), confirming the validity of the risk score modeling.

Study details: Assessment of a risk score model in 98 patients.

Disclosures: Dr. Abdou reported having no disclosures.

Citation:

Abdou Y et al. ASCO-SITC. Poster A3.